CARE for Blood Cancer Act of 2026
- Sponsor
- Rep. Barragán, Nanette Diaz [D-CA-44]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Oct 22, 2026
Bottom line
This bill creates a new federal program to enhance research, education, and access to care for blood cancer patients and communities at higher risk.
What it actually does
This bill establishes the National Blood Cancer Program within the Department of Health and Human Services. It aims to coordinate federal efforts, improve public and professional education, support individuals diagnosed with blood cancer and their caregivers, and fund research into awareness, education, diagnostics, and treatments for blood cancer.
Proponents argue
Supporters argue this program will centralize and strengthen federal efforts against blood cancer, leading to better public awareness, earlier detection, improved treatments, and reduced disparities, ultimately saving lives and improving quality of life for patients and their families.
Opponents contend
Critics might contend that while the goals are laudable, establishing a new, dedicated program could lead to bureaucratic inefficiencies or duplicate efforts already undertaken by existing agencies, potentially diverting resources from broader cancer research initiatives without clear evidence of added value over existing frameworks.
The bill is very concise and can be read and understood quickly, making it accessible for immediate evaluation.
Section 2(a) and 2(b)
National Blood Cancer Program Establishment and Goals
This section establishes the National Blood Cancer Program within the Department of Health and Human Services. Its primary goals are to develop public information and education programs, improve health professional training, support patients and caregivers, and evaluate these activities. The Secretary is directed to coordinate and support these efforts across federal agencies like the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Health Resources and Services Administration (HRSA).
Supporters argue
Supporters argue that a dedicated, coordinated national program is essential to focus resources and expertise on blood cancers, which are distinct from other cancer types, ensuring a comprehensive approach to research, education, and patient support.
Critics contend
Some might argue that existing federal agencies already have mandates and programs addressing cancer research and public health, and a new program might create redundancy or an additional layer of bureaucracy without significantly enhancing current efforts.
Tradeoffs
The tension lies between creating a focused program for a specific disease area versus integrating blood cancer efforts within broader, existing cancer initiatives to avoid fragmentation and potential resource dilution.
Section 3
Grants for Awareness and Education Research
This section authorizes the Secretary to award grants to eligible entities, including state, local, territorial, and Tribal health agencies, and qualified non-governmental entities. These grants are for conducting research on best practices for blood cancer awareness and education, covering areas like behavioral studies, risk factor identification, social marketing strategies, reducing disparities, and surveys of provider/public knowledge. Priority is given to communities with high risk or substantial incidence/mortality rates.
Section 4
Grants for Diagnostics and Treatment Research
This section authorizes the Secretary to award grants to institutions of higher education and academic medical centers. The grants are for research aimed at improving the availability of and access to blood cancer diagnostics and treatments. This includes developing new screening methods, novel treatment methods, investigating treatment effectiveness, identifying risk factors in disproportionately affected populations, and developing approaches for family history and genetic predisposition assessment.